Ruxozee 1.5% Cream 5g

Description

Ruxozee 1.5% Cream is a topical prescription medicine containing ruxolitinib, a Janus kinase inhibitor. It is applied to affected skin under medical supervision for inflammatory skin conditions such as atopic dermatitis and non-segmental vitiligo.

• Manufacturer Name: Horizon
• Drug Class: Topical Janus kinase (JAK1/JAK2) inhibitor
• Dosage Form: Topical Cream
• Storage: Store at controlled room temperature, away from excessive heat, moisture, and direct sunlight. Do not freeze. Keep the tube tightly closed and out of reach of children.
• Pack Size: Pack of 1

Ruxozee 1.5% Cream 5g Available Online in Pakistan

Dwatson offers Ruxozee 1.5% Cream 5g at Rs.1450, with fast, discreet delivery across Pakistan.

Ingredients

• Ruxolitinib 1.5% w/w

Benefits

• Topical treatment of mild-to-moderate atopic dermatitis when appropriate topical therapies are inadequate or unsuitable.
• May be prescribed for non-segmental vitiligo to help promote repigmentation of affected skin.
• Use only for the skin condition and body areas directed by a healthcare professional.

Usage & Safety

For Adult

• Apply a thin layer to affected areas twice daily, or exactly as directed by the prescriber.
• Rub in gently and wash hands after application unless the hands are being treated.
• Avoid applying to the eyes, mouth, mucous membranes, open wounds, or infected skin.
• Do not use over extensive body areas or for longer than directed without medical supervision.

For Children

• Use in children only on the advice of a dermatologist or qualified healthcare professional.
• Safety and dosing depend on the child’s age, diagnosis, affected body-surface area, and overall health.
• Do not use in children below the prescriber’s recommended age limit.
• Keep away from children to prevent accidental ingestion or inappropriate application.

Side Effects

• Common effects may include application-site acne, itching, redness, irritation, folliculitis, or peeling.
• Contact a healthcare professional if symptoms are severe, persistent, or worsening.
• Seek urgent medical care for signs of serious infection, unusual fever, persistent cough, painful skin lesions, unexplained weight loss, chest pain, shortness of breath, sudden weakness, or swelling and pain in a limb.
• Systemic JAK-inhibitor-related effects such as serious infections, malignancy, major cardiovascular events, or thrombosis are uncommon with topical use but require medical attention if suspected.

Contraindications

• Do not use in patients with a known allergy to ruxolitinib or any component of the cream.
• Do not apply to untreated serious skin infections or areas with active infection unless specifically directed by a healthcare professional.
• Use cautiously in patients with recurrent or serious infections, tuberculosis, hepatitis, immune-system disorders, blood disorders, cancer, or a history of blood clots or major cardiovascular disease.
• Do not combine with oral or injectable JAK inhibitors, biologic immunosuppressants, or other potent immunosuppressive medicines unless specifically prescribed.

Precautions & Warnings

• Avoid concurrent use with other JAK inhibitors or potent immunosuppressive medicines unless approved by the prescriber.
• Tell the healthcare professional about biologic medicines, systemic corticosteroids, chemotherapy, transplant medicines, or medicines that weaken the immune system.
• Do not apply other medicated creams, ointments, or cosmetics to the same area unless advised.
• No specific food interaction is expected with topical use.

Pregnancy

• Tell the healthcare professional if pregnant, planning pregnancy, or breastfeeding before use.
• Human pregnancy safety data are limited; use only when the expected benefit justifies any potential risk.
• Breastfeeding patients should seek medical advice before use and should not apply the cream to the nipple or breast area where the infant may ingest it.